therapies

Warren Cantor Tony Gershlick REFERENCE: Abstract 2404-3 SCAI-ACCi2 Late-Breaking Clinical Trials II: Acute Myocardial Infarction Warren Cantor, University of Toronto COMMENT: Tony Gershlick, Leicester

Nick Thatcher NICK THATCHER, Christie Hospital, Manchester There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cance

Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t

Bart Barlogie Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 BART BARLOGIE, University of Arkansas, Little Rock A treatment known as “total therapy

Kenneth Anderson Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston Multiple myeloma may soon be consi

Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro

Robert Mayer ROBERT MAYER, Dana-Farber Cancer Institute, Boston One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some

Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in

Richard Stone RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute New data shows that dasatinib is giving durable responses in patients with chronic phase

Zakari Aliyu REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta ZAKARI ALIYU, Howard University, Washington DC Nigeria has the highest incidence of sickle cell anemi

Jean-Yves Douillard Gordon McVie REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 Р27 September 2007 JEAN-YVES DOUILLARD, Centre Ren̩ Gauducheau, N

George Sopko

Uwe Zeymer REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida UWE ZEYMER, Herzzentrum Ludwigshafen, Germany The gl

REFERENCE: Abstract: Late Breaking Clinical Trials, Session 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LESLEE SHAW, Emory University, Atlanta COMMENT: DANI

Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO

Pierre Laurent-Puig Bill Hait REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris COMMEN

STEVEN NISSEN, Cleveland Clinic, OH REFERENCE: N Engl J Med 2007 356 Reporting from: American College of Cardiolgy New Orleans Two big studies published in the New England Journal of Medicine and pres